Published in Nucleic Acids Res on March 22, 2010
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol (2012) 2.10
Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci U S A (2011) 1.98
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog (2011) 1.90
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe (2010) 1.67
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology (2015) 1.43
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem (2012) 1.38
NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat Commun (2013) 1.36
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS One (2010) 1.28
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
APOBEC3A functions as a restriction factor of human papillomavirus. J Virol (2014) 1.24
Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol (2011) 1.18
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol (2011) 1.18
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood (2012) 1.15
Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio (2014) 1.15
APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol (2012) 1.14
APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol (2012) 1.14
The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol (2013) 1.13
Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol (2011) 1.12
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol (2010) 1.12
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat Commun (2013) 1.09
Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J Leukoc Biol (2013) 1.09
Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity. Virology (2010) 1.09
Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle (2013) 1.07
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer (2014) 1.07
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog (2014) 1.07
Repair of naturally occurring mismatches can induce mutations in flanking DNA. Elife (2014) 1.06
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J Virol (2013) 1.05
The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol (2010) 1.05
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J Virol (2011) 1.04
Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol (2010) 1.04
An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol (2012) 1.02
Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathog (2012) 1.02
Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J Biol Chem (2012) 1.02
Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties. Nucleic Acids Res (2013) 1.01
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00
Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem (2013) 0.99
Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J Biol Chem (2011) 0.99
Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol (2012) 0.99
Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat Struct Mol Biol (2015) 0.99
Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J Biol Chem (2011) 0.98
The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J Mol Biol (2013) 0.97
APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology (2012) 0.97
The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol (2011) 0.94
Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One (2013) 0.93
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93
Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors. Virology (2011) 0.93
Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology (2011) 0.92
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
Human Tribbles 3 protects nuclear DNA from cytidine deamination by APOBEC3A. J Biol Chem (2012) 0.92
Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. J Virol (2011) 0.91
Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One (2011) 0.91
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol (2014) 0.91
Variation of HIV-1 mutation spectra among cell types. J Virol (2013) 0.90
APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. Elife (2014) 0.90
IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol (2013) 0.90
New insights into an X-traordinary viral protein. Front Microbiol (2014) 0.90
AID/APOBEC deaminases and cancer. Oncoscience (2015) 0.89
Immune mechanisms of HIV control. Curr Opin Immunol (2010) 0.89
APOBEC3 Proteins in Viral Immunity. J Immunol (2015) 0.89
Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys. Retrovirology (2011) 0.89
The PKC/NF-κB Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers. Cancer Res (2015) 0.88
A biochemical analysis linking APOBEC3A to disparate HIV-1 restriction and skin cancer. J Biol Chem (2013) 0.88
APOBEC3 proteins and genomic stability: the high cost of a good defense. Cell Cycle (2012) 0.88
Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog (2015) 0.87
Human LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that affects LINE reverse transcriptase activity. Nucleic Acids Res (2013) 0.87
Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog (2014) 0.87
AID and APOBECs span the gap between innate and adaptive immunity. Front Microbiol (2014) 0.87
Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology (2013) 0.87
A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. Virology (2014) 0.86
Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. Med Microbiol Immunol (2014) 0.85
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Mol Biol Int (2012) 0.84
APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J Virol (2011) 0.84
Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol (2016) 0.83
Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-β/RUNX axis. Sci Adv (2015) 0.83
LINE-1 retrotransposable element DNA accumulates in HIV-1-infected cells. J Virol (2013) 0.83
Interaction of APOBEC3A with DNA assessed by atomic force microscopy. PLoS One (2014) 0.83
Retroviral restriction and dependency factors in primates and carnivores. Vet Immunol Immunopathol (2011) 0.83
The APOBEC Protein Family: United by Structure, Divergent in Function. Trends Biochem Sci (2016) 0.82
APOBEC3F determinants of HIV-1 Vif sensitivity. J Virol (2014) 0.82
APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics (2015) 0.82
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res (2003) 7.15
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell (2002) 5.14
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 3.76
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol (2006) 3.57
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem (2006) 3.03
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science (2008) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet (2007) 2.85
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol (2006) 2.40
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology (2006) 2.03
Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res (2004) 1.98
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 1.84
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun (2006) 1.76
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci U S A (2007) 1.73
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog (2009) 1.65
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol (2008) 1.50
Lymphocyte studies in asymptomatic cigarette smokers. A comparison between lung and peripheral blood. Am Rev Respir Dis (1977) 1.41
Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One (2009) 1.39
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol (2010) 1.34
Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol (2008) 1.25
APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J Gen Virol (2008) 1.23
Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol (2007) 1.13
Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog (2009) 1.10
The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology (2007) 1.08
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
CEM-T4 cells do not lack an APOBEC3G cofactor. PLoS Pathog (2009) 0.82
AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 7.12
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med (2010) 3.31
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Immunity through DNA deamination. Trends Biochem Sci (2003) 2.39
Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res (2012) 2.29
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
APOBEC3G targets specific virus species. J Virol (2004) 1.78
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (2010) 1.65
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (2009) 1.62
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett (2007) 1.62
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Virus identification in unknown tropical febrile illness cases using deep sequencing. PLoS Negl Trop Dis (2012) 1.52
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
The use of tinted contact lenses in the management of achromatopsia. Optometry (2007) 1.45
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep (2012) 1.40
Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem (2010) 1.38
Pillars article: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 2002. 418: 99-103. J Immunol (2015) 1.38
Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem (2012) 1.38
Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A (2007) 1.35
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28
Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife (2013) 1.28
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol (2012) 1.22
Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev (2006) 1.21
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood (2012) 1.15
MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells. Mol Immunol (2005) 1.13
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (2013) 1.13
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol (2010) 1.12
AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res (2009) 1.09
Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle (2013) 1.07
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer (2014) 1.07
Contribution of copy number variation in the regulation of complement activation locus to development of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.07
Competition of Escherichia coli DNA polymerases I, II and III with DNA Pol IV in stressed cells. PLoS One (2010) 1.07
The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One (2007) 1.04
HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. AIDS Res Hum Retroviruses (2012) 1.03
Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathog (2012) 1.02
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry (2012) 1.00
Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem (2013) 0.99
Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J Biol Chem (2011) 0.98
Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine (2005) 0.98
The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J Mol Biol (2013) 0.97
Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol (2008) 0.96
Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J Virol (2009) 0.95
DNA-dependent protein kinase inhibits AID-induced antibody gene conversion. PLoS Biol (2007) 0.94
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res (2015) 0.93
Unique DNA repair gene variations and potential associations with the primary antibody deficiency syndromes IgAD and CVID. PLoS One (2010) 0.93
Directed DNA deamination by AID/APOBEC3 in immunity. Curr Biol (2006) 0.91
Copy number variation in the complement factor H-related genes and age-related macular degeneration. Mol Vis (2011) 0.90
Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem (2012) 0.90